US FDA Approves Gilead's Bixlenvo for Once-Daily HIV Treatment
The US Food and Drug Administration (FDA) approves Gilead’s Bixlenvo, a once-daily single-tablet HIV treatment combining bictegravir and lenacapavir for virologically suppressed adults.
Bictegravir Lenacapavir | 01/09/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy